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Abstract
The prevalence of HIV in Vancouver, British Columbia was subject to two distinct periods of rapid
increase. The first occurred in the 1980s due to high incidence among men who have sex with men
(MSM), and the second occurred in the 1990s due to high incidence among injection drug users
(IDU). The purpose of this study was to estimate and model the trends in HIV prevalence in
Vancouver from 1980 to 2006. HIV prevalence data were entered into the UNAIDS/WHO
Estimation and Projection Package (EPP) where prevalence trends were estimated by fitting an
epidemiological model to the data. Epidemic curves were fit for IDU, MSM, street-based female sex
trade workers (FSW), and the general population. Using EPP, these curves were then aggregated
to produce a model of Vancouver's overall HIV prevalence. Of the 505 000 people over the age of
15 that reside in Vancouver, 6108 (ranging from 4979 to 7237) were living with HIV in the year
2006, giving an overall prevalence of 1.21 percent (ranging from 0.99 to 1.43 percent). The
subgroups of IDU and MSM account for the greatest proportion of HIV infections. Our model
estimates that the prevalence of HIV in Vancouver is greater than one percent, roughly 6 times
higher than Canada's national prevalence. These results suggest that HIV infection is having a
relatively large impact in Vancouver and that evidence-based prevention and harm reduction
strategies should be expanded.
Background
In Vancouver, British Columbia, the population sub-
groups most affected by HIV have experienced different
rates of infection over the course of the epidemic. In the
1980s, most HIV infections were accounted for by sexual
transmission among men who have sex with men (MSM),
and in the mid-1990s a rapid increase in HIV incidence
was observed among injection drug users (IDU) and
street-based female sex trade workers (FSW) [1,2].
Although this shift in HIV trends was well documented, it
has not been adequately quantified or characterized in the
historical context of the city's HIV epidemic.
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Measuring longitudinal trends in the prevalence of HIV is
essential to characterize the epidemic and to monitor
changes in high-risk population subgroups. As disease
prevalence reflects both incidence and mortality rates,
monitoring trends in HIV prevalence can provide insight
into the impact of events affecting HIV risk as well as sur-
vival, such as increased use of injection cocaine or the
introduction of highly active antiretroviral therapy
(HAART). Documenting HIV prevalence over time also
provides the denominator needed to calculate HIV-related
health indicators within a temporal frame, such as the
proportion of infected individuals receiving HAART or the
proportion with co-infections.
Despite the importance of measuring overall HIV preva-
lence, current prevalence data in Vancouver have been
limited to specific population subgroups and specific
points in time. The purpose of this study was to combine
estimates of HIV prevalence among population subgroups
in Vancouver in order to model the prevalence trends of
these subgroups and Vancouver's overall population lon-
gitudinally from 1980 to 2006.
Methods
A literature search was conducted using medical and sci-
entific databases (PubMed, Web of Science), national
websites (Public Health Agency of Canada, Statistics Can-
ada), and a general search engine (Google) in order to
identify all published and unpublished estimates of HIV
prevalence in Vancouver among MSM, IDU, FSW, and
pregnant women receiving antenatal testing (PW), a lower
risk population subgroup and reference point for the
remaining general population. Published and unpub-
lished estimates of MSM, IDU, and FSW population sizes
were also extracted. All data sources of HIV prevalence and
population sizes are listed in Table 1. Since the HIV prev-
alence among PW was used to reflect the prevalence of the
lower risk, remaining population, they were assigned a
large population size. Population estimates for the city of
Vancouver were taken from Statistics Canada [3]. The final
population subgroup sizes were based on previously pub-
lished estimates and peer-based discussions. Individuals
under 15 years of age were not included in our analyses as
data on this group are limited.
The HIV prevalence input assumptions for the year 2006
were based on the most recent available measures, all of
which were from the year 2003 or later. Vancouver's total
population over the age of 15 was estimated to be 505 000
[3]. The estimated sizes of the population subgroups are
as follows: MSM 20 000 (15 000 – 25 000), IDU 13 500
(10 000 – 15 000), FSW 1500 (1000 – 2000), PW 470 000
(477 000 – 463 000). All estimates of HIV and population
sizes are presented in Table 2.
All data were entered into the UNAIDS/WHO Estimation
and Projection Package (EPP) [4], where prevalence
trends for each population subgroup were estimated lon-
gitudinally by fitting an epidemic curve to the data for
each subgroup. EPP finds the curve of best fit by minimiz-
ing the log likelihood of several parameters, such as the
start year of the epidemic and the rate of HIV transmis-
sion. The epidemic curves that were modeled for popula-
tion subgroups were aggregated by EPP to find the best
Table 1: Model parameters and data sources of subgroup population sizes and HIV prevalence data
Key parameters Sources
Vancouver
population size Statistics Canada [3]
MSM*
population size Population surveys, capture-recapture estimates [11,19]
HIV prevalence Cohort and cross-sectional surveys [20-23]
IDU*
population size Population surveys, capture-recapture estimates [11,24]
HIV prevalence Cohort and cross-sectional surveys [1,25-29]
FSW*
population size Peer-based discussions
HIV prevalence Community-based studies of FSW [1,25,30]
General population*†
population size Remaining population
HIV prevalence Antenatal seroprevalence studies [31,32]
*HIV prevalence estimates each included data from the Health Canada Inventory of HIV Prevalence Studies [33].
†The prevalence of pregnant women receiving antenatal testing was used to impute the estimate for the general population.
MSM, men who have sex with men; IDU, injection drug users; FSW, street-based female sex trade worker.Harm Reduction Journal 2009, 6:5 http://www.harmreductionjournal.com/content/6/1/5
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fitting curve that models the overall trends of Vancouver's
HIV prevalence. Based on the estimated population sizes
(Table 2), a low growth model, a high growth model, and
an intermediate model, reflecting our best estimate, were
produced for the overall population.
Findings
Table 3 provides the estimates of the number of HIV-
infected individuals from the specific population sub-
groups and Vancouver's entire population for the year
2006. We estimate that a total of 6108 (ranging from 4979
to 7237) men and women were living with HIV in the year
2006, producing an overall HIV prevalence of 1.21%
(ranging from 0.99% to 1.43%). Our models estimate
that MSM and IDU subgroups contributed the greatest
number of infections, with 3000 (ranging from 2250 to
3750) and 2295 (ranging from 2040 to 2550) individuals,
respectively.
The EPP model depicting the prevalence of HIV from
1980 to 2006 in each subgroup is shown in Figure 1. The
model illustrates the rise in HIV prevalence among MSM
in the 1980s as well as the rapid increase in prevalence
among IDU and FSW in the 1990s. The upward trends of
the model project the potential for moderate increases in
HIV prevalence within each of these population sub-
groups.
Figure 2 characterizes the trend in Vancouver's overall HIV
prevalence since 1980. The model depicts two rapid
increases in HIV prevalence, the first in the mid-1980s and
the second in the mid-1990s, and the upward trend of the
model projects the potential for a moderate future
increase in Vancouver's overall HIV prevalence.
Discussion
In the year 2006, there were approximately 6108 (ranging
from 4979 to 7237) people living in Vancouver that were
infected with HIV. Populations of IDU and MSM contrib-
uted the largest number of infections. Although HIV prev-
alence was highest among FSW, due to the relatively small
size of this subgroup, they accounted for only a small pro-
portion of the total HIV infections in Vancouver. Few total
infections were from PW, our reference point for the gen-
eral population. Our overall estimate indicates that the
prevalence of HIV in Vancouver was approximately 1.21%
(ranging from 0.99% to 1.43%) in the year 2006 and the
upward trend in our model suggests that there is potential
for this value to increase slightly in the future.
Table 2: Estimated population subgroup sizes and HIV prevalence for persons 15 years of age and older living in Vancouver
Transmission group Estimated population size (low and high estimates) HIV prevalence, 2006*
MSM 20 000 (15 000 – 25 000) 15.0%
IDU 13 500 (12 000 – 15 000) 17.0%
FSW 1500 (1000 – 2000) 26.0%
General population† 470 000 (477 000 – 463 000) 0.09%
*Prevalence input assumptions for the year 2006 were based on the most recent available measures, all of which were from the year 2003 or later.
†The prevalence of pregnant women receiving antenatal testing was used to impute the estimate for the general population.
MSM, men who have sex with men; IDU, injection drug users; FSW, street-based female sex trade worker.
Table 3: Estimated number of persons infected with HIV in Vancouver, 2006
Variable HIV Infected
Low Estimate Middle Estimate High Estimate
Transmission groups
MSM 2250 3000 3750
IDU 2040 2295 2550
FSW 260 390 520
General population† 429 423 417
Total population
Males 3585 4459 5355
Females 1394 1649 1882
Total infected 4979 6108 7237
Overall prevalence 0.99% 1.21% 1.43%
†The prevalence of pregnant women receiving antenatal testing was used to impute the estimate for the general population.
MSM, men who have sex with men; IDU, injection drug users; FSW, street-based female sex trade worker.Harm Reduction Journal 2009, 6:5 http://www.harmreductionjournal.com/content/6/1/5
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Our model successfully represents Vancouver's two docu-
mented periods of rapid increase in HIV prevalence [1,2].
The first rise in Vancouver's prevalence occurred in the
mid-1980s as a consequence of high HIV incidence
among MSM [2]. However, the pace of this increase was
slowed in the late 1980s, largely as a result of mortality
associated with the disease in the MSM subgroup [5]. The
second period of rapid increase resulted from high rates of
HIV transmission among Vancouver's IDU and FSW sub-
groups during the mid-1990s, at which time the preva-
lence of HIV in Vancouver approached 1%. Since this
time, our model suggests that the prevalence of HIV in
Vancouver has steadily increased and has the potential to
increase in the future. Recent increases in prevalence may
be attributed to increases in transmission among individ-
uals with detectable HIV viral loads and increased survival
among individuals on HAART [6-9].
Vancouver's HIV epidemic remains concentrated in high-
risk subgroups of MSM, IDU, and FSW, like other large
Canadian cities such as Montreal and Toronto [10]. What
distinguishes Vancouver's situation from these other cit-
ies, however, is its relatively large population of high-risk
individuals, particularly IDU. For example, a previous
study [11] estimated that the city of Vancouver has a
greater number of IDU than Montreal and a comparable
number to that found in Toronto, despite Vancouver hav-
ing a smaller overall population size. Furthermore, Van-
couver's estimated IDU population of 13 500 individuals
represents between 11% and 18% of Canada's total IDU
population, which has been estimated to be between 75
000 and 125 000 individuals [12]. Given the relatively
large IDU and MSM populations in Vancouver, it is not
surprising that our model indicates Vancouver's overall
HIV prevalence passed the 1% mark in the 1990s, during
which time rapid transmission of HIV was observed
among IDU [1]. Unfortunately, despite the expansion of
needle exchange programs and the implementation of
Vancouver's safe injection site, which have both shown
the potential to decrease HIV incidence [13-16], transmis-
sion of HIV remains high within IDU populations [6], a
finding that is reflected in our model of IDU. Similarly,
our model suggests that since the mid-1990s the preva-
lence of HIV among MSM has been increasing, a finding
that is also consistent with recent incidence data [7].
As with any estimation of HIV prevalence, the validity of
our model is dependent on the validity of the data
sources. Unfortunately, due to limitations in the availabil-
ity of prevalence data, it was necessary to combine differ-
ent types of data, which may have led to either
overestimates or underestimates of prevalence for any of
the subgroups. For example, the most recent prevalence
data on MSM was derived from self-report of HIV status
and these data may underestimate prevalence. Further-
more, because the HIV prevalence among high-risk sub-
groups is not measured annually, our 2006 input
assumptions were based on the most recent available
measures, some of which were from the years 2003–2005.
It is possible that these values have changed, and there is
a need for updated seroprevalence data. Another limita-
tion includes our inability to model the prevalence trends
of all high-risk population subgroups, such as individuals
with mental health disorders, although this subgroup
could potentially overlap with the IDU subgroup. Conse-
quently, the prevalence estimate for Vancouver's total
population, which relied on data from pregnant women
Middle estimates of HIV prevalence for population subgroups  in Vancouver, 1980–2006 Figure 1
Middle estimates of HIV prevalence for population 
subgroups in Vancouver, 1980–2006. *The prevalence of 
pregnant women receiving antenatal testing was used to 
impute the estimate for the general population. MSM, men 
who have sex with men; IDU, injection drug users; FSW, 
street-based female sex trade worker; PW, pregnant women 
receiving antenatal testing.
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to reflect HIV prevalence outside of the high-risk popula-
tion subgroups, may be an underestimate. Finally, our
model relied on the UNAIDS EPP program, which is una-
ble to account for all the epidemiological factors that
could potentially affect HIV prevalence. Importantly,
however, this program provides an accessible method for
modeling HIV prevalence and may be useful in other set-
tings.
Our model indicates that the prevalence of HIV in the city
of Vancouver is approximately 6 times higher than Can-
ada's national prevalence [17,18]. Further, the upward
trend of our model suggests that there is potential for
future increases in Vancouver's overall HIV prevalence
[19-33]. These findings suggest that HIV infection is hav-
ing a large impact in Vancouver and that evidence-based
prevention and harm reduction strategies, particularly
those targeted at high-risk population subgroups, should
continue to be expanded and evaluated.
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